Physician profile
Rolando Ortiz
NPI 1407006141
$1,419.79
in general payments reported to CMS, 2019-2025
10 companies · $613 in 2025
The $613 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $54.21 · 2022: $168 · 2023: $61.82 · 2024: $281 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $476.72 | 2019-2025 | Ortho-K Contact Lens, Myday Contact Lens, Synergeyes Contact Lens |
| Ani Pharmaceuticals, INC. | $214.54 | 2024-2025 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $209.80 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $135.61 | 2019-2020 | |
| Oyster Point Pharma, INC. | $124.94 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $81.07 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Optos, INC. | $64.78 | 2019 | |
| Dompe US, INC. | $31.21 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.